-
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
-
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
-
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
